NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trialbenzinga.comTTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial.
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025benzinga.comNovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.
NovoCure Surpasses Q1 Expectationsfool.comNovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.
NovoCure (NVCR) Q4 2024 Earnings Call Transcriptfool.comNVCR earnings call for the period ending December 31, 2024.
NovoCure Q4 EPS Misses, Revenue Matchesfool.comNovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025benzinga.comNovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion.
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'benzinga.comOn CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."
